GlassScriptPhysician profile
Jafet Baxter
NPI 1851886915
$2,042.54
in general payments reported to CMS, 2019-2025
13 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $42.65 · 2024: $906 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $350.50 | 2024-2025 | Ozempic, Rybelsus, Tresiba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.07 | 2024-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $333.76 | 2024-2025 | Breztri, Airsupra |
| Pfizer INC. | $289.98 | 2024-2025 | |
| Amgen INC. | $215.23 | 2023-2025 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $133.50 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $88.26 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $80.79 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $69.10 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Esperion Therapeutics, INC. | $65.53 | 2024 | Nexletol |
| Exact Sciences Corporation | $44.28 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $13.85 | 2025 | Gardasil 9, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $12.69 | 2023 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jafet Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.